<DOC>
	<DOCNO>NCT00576979</DOCNO>
	<brief_summary>RATIONALE : Giving intensity modulate radiation therapy ( IMRT ) chemotherapy , etoposide cyclophosphamide , donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving IMRT together chemotherapy transplant may stop happen . PURPOSE : This phase I/II trial study side effect best dose intensity-modulated radiation therapy ( IMRT ) give together etoposide cyclophosphamide follow donor stem cell transplant see well work treat patient relapsed refractory acute lymphoblastic leukemia ( ALL ) acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Intensity-Modulated Radiation Therapy , Etoposide , Cyclophosphamide Followed By Donor Stem Cell Transplant Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . To establish maximum tolerate dose [ MTD ] large field image-guided IMRT , use helical tomotherapy give combination intravenous cyclophosphamide VP-16 preparative regimen allogeneic hematopoietic stem cell transplantation ( HSCT ) human leukocyte antigen ( HLA ) -identical sibling unrelated donor patient ALL AML induction failure relapse . ( Phase I ) II . To describe toxicity dose level standard . ( Phase I ) III . To collect data radiation dose normal organ bone marrow use tomotherapy target total-body irradiation ( TBI ) . ( Phase I ) IV . To estimate overall survival probability , disease free survival probability relapse rate associate regimen . ( Phase II ) V. To characterize treatment related mortality toxicity profile ( early/late ) associate regimen . ( Phase II ) VI . To descriptively compare outcomes patient treat protocol comparable patient population condition whole body radiation . ( Phase II ) OUTLINE : This phase I , dose-escalation study intensity-modulated radiation therapy ( IMRT ) follow phase II study . PREPARATIVE REGIMEN : Patients undergo IMRT use helical tomotherapy twice daily day -10 -6 -10 -7 . Patients also receive etoposide intravenously ( IV ) day -6 -5 cyclophosphamide IV day -4 -3 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell bone marrow transplantation day -1 day 0 . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Patients acute lymphocytic leukemia acute myelogenous leukemia first second remission ( i.e. , fail remission induction therapy relapse beyond second remission ) All candidate study must human leukocyte antigen ( HLA ) ( A , B , C , DR ) identical sibling willing donate bone marrow prim blood stem cell 10/10 allele match unrelated donor ; single allele mismatch A , B , C , DR , DQ KIR mismatch C allow ; ABO blood group combination donor/recipient acceptable since even major ABO compatibility deal various technique Prior therapy VP16 , Busulfan , Cytoxan allow A cardiac evaluation electrocardiogram show ischemic change abnormal rhythm ejection fraction &gt; = 50 % establish multi gated acquisition scan ( MUGA ) echocardiogram Patients must serum creatinine less equal 1.2 creatinine clearance &gt; 80 ml/min A bilirubin less equal 1.5 Serum glutamic oxaloacetic transaminase ( SGOT ) less 5 time upper limit normal Serum glutamate pyruvate transaminase ( SGPT ) less 5 time upper limit normal Pulmonary functioning test include diffuse capacity carbon monoxide ( DLCO ) perform ; force expiratory volume one second ( FEV1 ) DLCO great 50 % predict normal value The time end last induction reinduction attempt &gt; = 14 day Signed informed consent form approve Institutional Review Board ( IRB ) require DONOR : Any sibling donor histocompatible prospective recipient consider suitable donor Donors exclude psychological medical reason unable tolerate procedure Donor able donate peripheral blood stem cell bone marrow Prior radiation therapy would exclude use totalbody irradiation Patients undergone bone marrow transplantation previously relapse Patients psychological medical condition patient physician deems unacceptable proceed allogeneic bone marrow transplant Pregnancy Electrocardiogram ( EKG ) show ischemic change abnormal rhythm and/or echocardiogram MUGA scan show abnormal wall motion ejection fraction &lt; 50 %</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>